GlobeNewswire

ObsEva Announces Third Quarter 2019 Financial Results

Share



– Reports Update on Three Women’s Health Product Candidates –

Focusing on Phase 3 Programs for Linzagolix and the Phase 2
Program for OBE022

– Company to Host Conference Call/Webcast Today at 8 am ET/2pm CET –

                       

GENEVA, Switzerland and BOSTON, MA (November 7, 2019) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the third quarter ended September 30, 2019 and announced top line results of the IMPLANT 4 trial.

"Despite the unexpected results for IMPLANT 4, we remain optimistic and committed to the development of our innovative pipeline with potentially best in class product candidates for serving unmet medical needs of millions of women.  In particular, we are looking forward to PRIMROSE 2 study top line results, which we expect to announce this quarter” said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva.

Pipeline Update

1.       Nolasiban

IMPLANT 4 study did not meet primary endpoint: The Company has decided to discontinue the current development of nolasiban for IVF and will be exploring potential repositioning of the product.

2.       Linzagolix

· Completed Patient Randomization for Two Pivotal Phase 3 trials For Women with Uterine Fibroids (PRIMROSE 1 and PRIMROSE 2):   The studies include approximately 1,000 women in total with heavy menstrual bleeding (HMB) associated with uterine fibroids. The efficacy and safety of two oral doses of linzagolix are being studied, including 100mg once daily without hormonal add-back therapy (ABT) and 200mg once daily with ABT.

· Positive Phase 2b (EDELWEISS 1) Results Presented at the American Society of Reproductive Medicine (ASRM) Annual Meeting : ObsEva presented positive 52-week results of linzagolix for treating endometriosis-associated pain. 
· Phase 3 trials EDELWEISS 2 (U.S.) and EDELWEISS 3 (U.S. and Europe) Currently Enrolling Patients :  Each trial will enroll approximately 450 women with endometriosis-associated pain, and will include two oral doses of linzagolix, 75mg once daily without low-dose ABT and 200mg once daily with ABT. 


                                                                                                                                        
3.       OBE022 To Delay Preterm Birth


· Data Monitoring Committee Recommended Continuation of Phase 2 Study in Europe (PROLONG): In July 2019, the independent data monitoring committee (IDMC) recommended continuing the ongoing PROLONG trial with no modifications based upon the first 30 patients enrolled in Part B.  Part B is the multicenter, randomized, double-blind, placebo-controlled portion of the trial that will enroll up to 120 patients with preterm labor at a gestational age of between 24 and 34 weeks.


· 

Anticipated Near-Term Milestones

ObsEva expects to achieve the following clinical and regulatory milestones in 2019 - 2020:

Fourth quarter 2019

  • Linzagolix: Report six-month primary endpoint data from the PRIMROSE 2 Phase 3 trial (U.S. and Europe) to treat HMB due to uterine fibroids.
     
  • OBE022: Receive interim update in 60 patients dosed in Part B of the PROLONG Phase 2a trial in acute pre-term labor and decide next steps in development.

Second Quarter 2020

·Linzagolix:  Report six-month primary endpoint data from the Phase 3 PRIMROSE 1 trial (U.S.) of linzagolix for the treatment of HMB due to uterine fibroids.

Second Half 2020

  • Linzagolix:
    • Read-out 12 month data for PRIMROSE 1 and PRIMROSE 2
    • Conduct pre-submission meeting with the European Medicines Agency and the U.S. Food and Drug Administration for uterine fibroid indication.
       
  • OBEO22: Report PROLONG study final results

Third Quarter 2019 Financial Results

Net loss for the third quarter of 2019 was $27.6 million, or $0.63 per share, compared with a net loss of $18.6 million, or $0.42 per share, for the third quarter of 2018.  Research and development expenses were $21.9 million and general and administrative expenses were $4.9 million for the third quarter of 2019, compared with $15.9 million and $3.1 million, respectively, for the third quarter of 2018.  The net loss for the third quarter of 2019 included non-cash expenses of $3.0 million for stock-based compensation, compared with $2.0 million in the prior-year period.

As of September 30, 2019, the Company had cash and cash equivalents of $91.0 million, compared with $138.6 million as of December 31, 2018.

The full Q3 2019 financial report shall be available from November 11, 2019, in the financial reports section of the Company’s website.

To access the financial reports section of the Company’s website, please click [here].
To access the Q3 2019 financial report directly, please click [here].

Conference Call Today

ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to provide a business update and discuss the third quarter results.  Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 9273485.  A live or archived webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website www.ObsEva.com.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, the Risk Factors filed as Exhibit 99.1 to ObsEva’s Form 6-K filed on August 7, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

Consolidated Statements of Comprehensive Loss

     Three-month period
ended September 30,
    Nine-Month Period
Ended September 30,
 
(in USD ’000, except share and per share data) - unaudited   2019     2018     2019     2018  
Operating income other than revenue     5       2       11       10  
OPERATING EXPENSES                                
Research and development expenses     (21,935 )     (15,909 )     (70,513 )     (46,945 )
General and administrative expenses     (4,865 )     (3,137 )     (16,306 )     (10,287 )
Total operating expenses     (26,800 )     (19,045 )     (86,819 )     (57,231 )
OPERATING LOSS     (26,795 )     (19,043 )     (86,808 )     (57,221 )
Finance income     219       430       425       616  
Finance expense     (1,021 )           (1,608 )      
NET LOSS BEFORE TAX     (27,597 )     (18,613 )     (87,991 )     (56,605 )
Income tax (expense)     (10 )     23       (51 )     23  
NET LOSS FOR THE PERIOD     (27,607 )     (18,590 )     (88,042 )     (56,582 )
Net loss per share                                
Basic     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Diluted     (0.63 )     (0.42 )     (2.01 )     (1.45 )
Weighted Average Number of Shares Outstanding     43,739,938       43,196,686       43,693,245       39,092,256  

Consolidated Balance Sheets

(in USD ’000) - unaudited   September 30,
2019
    December 31,
2018
 
ASSETS                
Current assets                
Cash and cash equivalents     91,017       138,640  
Other receivables     776       885  
Prepaid expenses     5,964       5,715  
Total current assets     97,757       145,240  
Non-current assets                
Right-of-use assets     2,202        
Furniture, fixtures and equipment     261       319  
Intangible assets     26,608       21,608  
Other long-term assets     270       273  
Total non-current assets     29,341       22,200  
Total assets     127,098       167,440  
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities                
Current tax liability     46        
Other payables and current liabilities     6,515       2,766  
Accrued expenses     19,595       14,163  
Current lease liabilities     598        
Total current liabilities     26,754       16,929  
Non-current liabilities                
Non-current lease liabilities     1,665        
Non-current borrowings     24,830        
Post-employment obligations     3,608       3,547  
Other long-term liabilities     414       48  
Total non-current liabilities     30,517       3,595  
Shareholders’ equity                
Share capital     3,448       3,420  
Share premium     318,226       314,565  
Reserves     20,122       12,858  
Accumulated losses     (271,969 )     (183,927 )
Total shareholders’ equity     69,827       146,916  
Total liabilities and shareholders’ equity     127,098       167,440  

###

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Maha Energy AB (publ) (“Maha” or the “Company”) announce change of time for Question and Answer Session Wednesday 13 November11.11.2019 22:00:00 CETPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm November 11, 2019 Maha Energy AB (publ) (“Maha” or the “Company”) announce change of time for Question and Answer Session Wednesday 13 November Earlier today, the Company announced it would be holding a Question and Answer Session on Wednesday 13 November at 4 PM CET. The time has been changed to 5 PM (CET) the same day. The webcast link will be posted on the Company’s website and is as follows: https://www.youtube.com/watch?v=xOs_y_-OS3M&feature=youtu.be Shareholders and investors can pose questions at the time of the live session, or questions can also be sent ahead of time to: victoria@mahaenergy.ca Adviser Certified Advisor: FNCA Sweden AB, info@fnca.se, Telephone: +46-8-528 00 399. For more information, please contact: Jonas Lindvall (CEO) Tel: +1 403 454 7560 Email: jonas@mahaenergy.ca or Ron Panchuk (EVP) Tel: +1 403 454 7560 Email: ron@mahaenergy.ca Miscellaneous The informatio

Valberedning nominerar Jesper Söderqvist till Arcomas styrelse11.11.2019 18:01:00 CETPress release

11 november 2019 PRESSRELEASE Valberedning nominerar Jesper Söderqvist till Arcomas styrelse Valberedningen i Arcoma AB meddelar idag att den avser att nominera Jesper Söderqvist som ordinarie medlem i bolagets styrelse vid Årsmötet 20 maj 2020. Valberedningen återkommer med sitt fullständiga förslag i samband med kallelse till Årsmötet. För ytterligare information var god kontakta: Lars Kvarnhem, styrelsens ordförande Telefon: 070-512 00 21 E-mail: lars.kvarnhem@priego.se Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 11 november 2019, kl. 18:00 För mer information om Arcoma, besök www.arcoma.se Attachment 191111 Pressrelease Valberedning nominerar Jesper Söderqvist

Jesper Söderqvist lämnar sin VD-post andra kvartalet 2020 och tar plats i Arcomas styrelse11.11.2019 18:00:00 CETPress release

11 november 2019 PRESSRELEASE Jesper Söderqvist lämnar sin VD-post andra kvartalet 2020 och tar plats i Arcomas styrelse Jesper Söderqvist har meddelat styrelsen att han kommer lämna sin VD-post under andra kvartalet 2020. Samtidigt har valberedningen idag också meddelat att den avser nominera Jesper Söderqvist till Arcomas styrelse vid Årsmötet 2020. Jesper Söderqvist har enligt sitt anställningsavtal sex månaders uppsägningstid och kommer att fortsätta i sin nuvarande roll tillsvidare, han lämnar VD-posten i Arcoma under andra kvartalet 2020. Styrelsen kommer nu att påbörja rekrytering av en efterträdare. ”Jesper har hjälpt oss att förstärka Arcoma ytterligare. Han har byggt vidare på vår grund för fortsatt positiv utveckling. Tillsammans med vårt Management Team har han arbetat intensivt och framgångsrikt med fokusering på starka strategiska samarbeten och ett tydligt fokus på operativa förbättringar. Detta har lett till att Arcoma idag står väl rustat för en fortsatt positiv försäl

Arion Bank: Transactions in relation to a share buyback programme11.11.2019 16:41:00 CETPress release

In week 45 Arion Bank purchased own shares on Nasdaq Iceland and Swedish Depository Receipts (SDR) on Nasdaq Stockholm. See further details below. Share buyback on Nasdaq Iceland Week Date Time Number of shares Share price Purchase price (ISK) Number of shares owned by Arion bank after trade 45 04/11/2019 10:14 500,000 79.5 39,750,000 1,299,899 45 04/11/2019 14:04 300,000 79.3 23,790,000 1,599,899 45 05/11/2019 09:51 850,000 80.1 68,085,000 2,449,899 45 06/11/2019 09:49 600,000 78.5 47,100,000 3,049,899 45 06/11/2019 13:46 300,000 78.8 23,640,000 3,349,899 45 07/11/2019 09:39 550,000 79.3 43,615,000 3,899,899 45 07/11/2019 09:39 5,000 79.3 396,500 3,904,899 45 07/11/2019 09:57 300,000 79.3 23,790,000 4,204,899 45 08/11/2019 10:15 558,000 79.3 44,249,400 4,762,899 45 08/11/2019 10:16 300,000 79.3 23,790,000 5,062,899 45 08/11/2019 10:23 60,000 79.3 4,758,000 5,122,899 Week 45 Total 4,323,000 342,963,900 Buyback of SDR’s on Nasdaq Stockholm Week Date Time Number of SDR's Price per SDR Pu

Awilco Drilling PLC: Primary Insider Disclosure11.11.2019 16:22:00 CETPress release

Awilco Drilling PLC (AWDR) announces that on 11th November 2019, the following synthetic share transactions occurred: Roddy Smith has had 55,395 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of NOK 17.87. After this transaction and as of today, Roddy Smith, holds 133,517 synthetic shares. Ian Wilson has had 55,395 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of NOK 17.87. After this transaction and as of today, Ian Wilson holds 115,454 synthetic shares. Claus Mørch has had 49,399 synthetic shares vested in AWDR automatically exercised under the Synthetic Share Plan at a price of at NOK 17.87. After this transaction and as of today, Claus Mørch holds no further synthetic shares. Aberdeen, 11 November 2019 For further information please contact: Jens Berge, CEO Phone: +44 1224 737900 Cathrine Haavind, IR Manager Phone: +47 9342 8464 Email: ch@awilcodrilling.com This information is sub

Awilco Drilling PLC: Minutes of Meeting from General Meeting11.11.2019 13:31:00 CETPress release

A General Meeting of Awilco Drilling PLC (Ticker: AWDR) was held Monday 11 November 2019 at 12:00 p.m. (UK time), at the Company’s offices, 2 Kingshill Park, Venture Drive, Arnhall Business Park, Westhill, Aberdeen AB32 6FL, UK. Each of the resolutions set out in the Meeting Notice were duly passed. The signed minutes of meeting are attached hereto. The Meeting Notice and Appendices are available on our website www.awilcodrilling.com, under ‘Investor Relations/General Meetings’. Aberdeen, 11 November 2019 For further information please contact: Jens Berge, CEO Phone: +44 1224 737900 Cathrine Haavind, IR Manager Phone: +47 93 42 84 64 Email: ch@awilcodrilling.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment AWDR GM Meeting Minutes 11 November 2019